These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 28631599)

  • 1. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
    Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
    Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents.
    Rodrigo GJ; Neffen H
    Pediatr Allergy Immunol; 2015 Sep; 26(6):551-6. PubMed ID: 25963882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials.
    Corren J; Kavati A; Ortiz B; Vegesna A; Colby JA; Ruiz K; Panettieri RA
    Curr Med Res Opin; 2018 Jan; 34(1):65-80. PubMed ID: 29057669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
    Abraham I; Alhossan A; Lee CS; Kutbi H; MacDonald K
    Allergy; 2016 May; 71(5):593-610. PubMed ID: 26644231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.
    Bousquet J; Humbert M; Gibson PG; Kostikas K; Jaumont X; Pfister P; Nissen F
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2702-2714. PubMed ID: 33486142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
    Tarraf HN; Masoud HH; Zidan M; Wahba B
    J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis.
    Fu Z; Xu Y; Cai C
    J Asthma; 2021 Oct; 58(10):1350-1358. PubMed ID: 32602383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review.
    Colombo GL; Di Matteo S; Martinotti C; Oselin M; Valentino MC; Bruno GM; Pitotti C; Menzella F
    Ther Adv Respir Dis; 2019; 13():1753466619841350. PubMed ID: 31035904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results.
    Zazzali JL; Raimundo KP; Trzaskoma B; Rosén KE; Schatz M
    Allergy Asthma Proc; 2015; 36(4):283-92. PubMed ID: 26108086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia].
    Morales-Múnera O; Pedraza Á; Niño-Serna L
    Rev Alerg Mex; 2018; 65(3):222-232. PubMed ID: 30176200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma.
    Al-Ahmad M; Arifhodzic N; Nurkic J; Maher A; Rodriguez-Bouza T; Al-Ahmed N; Sadek A; Jusufovic E
    Med Princ Pract; 2018; 27(3):260-266. PubMed ID: 29414831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.
    Chen HC; Huang CD; Chang E; Kuo HP
    BMC Pulm Med; 2016 Jan; 16():3. PubMed ID: 26747278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
    Di Bona D; Fiorino I; Taurino M; Frisenda F; Minenna E; Pasculli C; Kourtis G; Rucco AS; Nico A; Albanesi M; Giliberti L; D'Elia L; Caiaffa MF; Macchia L
    Respir Med; 2017 Sep; 130():55-60. PubMed ID: 29206634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma.
    Har D; Lee MJ
    Allergy Asthma Proc; 2019 Jan; 40(1):35-40. PubMed ID: 30582494
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.